NASDAQ:PCVX Stock Quote

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious vaccine-related adverse events.

-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) --

SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company’s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants.

Investors are questioning the value of small-cap stocks, as reflected by Russell 2000's 15% drop. Some top stocks saw even bigger declines.

-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 --

The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.

SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.

-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data --

SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference in New York on Thursday, February 6, 2025 at 9:30 a.m. ET / 6:30 a.m. PT.

-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later --